Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review

Clinical Rheumatology

Volumn 34, Issue 1, 2015, Pages 99-105

  Ge, Yongpeng ^a   Peng, Qinglin ^a   Zhang, Sigong ^a   Zhou, Hang ^a   Lu, Xin ^a   Wang, Guochun ^a  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

Cyclophosphamide; Idiopathic inflammatory myopathy; Interstitial lung disease

Indexed keywords

ANTIEMETIC AGENT; AZATHIOPRINE; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLATE MOFETIL; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL (TOPIC); CREATINE KINASE BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; ENDOCARDITIS; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; JUVENILE DERMATOMYOSITIS; LUNG ASPERGILLOSIS; LUNG FUNCTION; LUNG FUNCTION TEST; LYMPHOCYTOPENIA; MUSCLE FUNCTION; MUSCLE STRENGTH; MYOSITIS; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SYSTEMATIC REVIEW; TOTAL LUNG CAPACITY; URINARY TRACT INFECTION; LUNG DISEASES, INTERSTITIAL; TREATMENT OUTCOME;

CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MYOSITIS; TREATMENT OUTCOME;

EID: 84922004367     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2803-z     Document Type: Article

References (19)

1. Chen YJ, Wu CY, Shen JL (2007) Predicting factors of interstitial lung disease in dermatomyositis and polymyositis. Acta Derm Venereol 87:33–38
2. Connors GR, Christopher-Stine L, Oddis CV et al (2010) Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 138:1464–1474
3. Labirua A, Lundberg IE (2010) Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol 22:633–638
4. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347
5. Cronin ME, Miller FW, Hicks JE et al (1989) The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 16:1225–1228
6. Kuroda H, Morinaga H, Satoh C et al (2003) Clinical study of 10 cases of acute or subacute interstitial pneumonia associated with dermatomyositis. Mod Rheumatol 13:313–318
7. Schnabel A, Reuter M, Biederer J et al (2003) Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 32:273–284
8. Riley P, Maillard SM, Wedderburn LR et al (2004) Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology 43:491–496
9. Meyer O, Hayem G, Palazzo E et al (2005) Interstitial lung disease due to polymyositis or dermatomyositis: effect of a 6-month course of i.v. pulse cyclophosphamide. Clin Exp Rheumatol 23:724–724
10. Kameda H, Nagasawa H, Ogawa H et al (2005) Combination therapy with corticosteroids, cyclosporine A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 32:1719–1726
11. Yamasaki Y, Yamada H, Yamasaki M et al (2007) Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 46:124–130
12. Shi JH, Xu WB, Liu HR et al (2008) Clinico-pathological manifestions in interstitial lung diseases associated with polymyositis-dermatomyositis. Chin J Tuberc Respir Dis 31:250–254
13. Marie I, Hatron PY, Dominique S et al (2011) Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 63:3439–3947
14. Zheng RZ (2012) Clinical analysis of intravenous cyclophosphamide therapy for steroid-resistant polymyositis/dermatomyositis. Dissertation, University of Shandong
15. Mira-Avendano IC, Parambil JG, Yadav R et al (2013) A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med 107:890–896
16. Nagappa M, Taly AB, Sinha S et al (2013) Efficacy and limitations of pulse cyclophosphamide therapy in polymyositis and dermatomyositis. J Clin Neuromuscul Dis 14:161–168
17. American Thoracic Society, European Respiratory Society (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 161:646–664
18. Ingegnoli F, Lubatti C, Ingegnoli A et al (2012) Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature. Autoimmun Rev 11:335–340
19. de Groot K, Dwomoa ADU, Savage CO et al (2001) The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 16:2018–2027